

Application No. 09/237,981  
RCE and Reply to Office Action of 11/19/2003

### REMARKS/ARGUMENTS

All pending claims have been amended to correct numbering as directed by the Examiner. In response to the Examiner's rejection under 35 USC §112, all pending claims have been amended to depend from independent claim 66, which has been amended to clarify the claimed antibodies bind to Del-1 polypeptides having sequences disclosed in the specification as identified by SEQ ID NO, as well as fragments thereof. It is believed that the amendments now place all claims in condition for allowance in keeping with the Examiner's determination of conditional allowability of pending claims 72 – 75 in which human Del-1 polypeptides were identified by SEQ ID. Amended claim 66 provides a Markush group including the SEQ ID for human (SEQ ID NOS: 30 and 31) as well as murine Del-1 (SEQ ID NOS: 10 and 29) as disclosed in the specification.

For the reasons stated herein, the Applicant respectfully submits that independent claim 66 is allowable and that the dependent claims are, in turn, also allowable. Applicant respectfully requests allowance of the claims at an early date. The Commissioner is authorized to charge any additional fees incurred in this application or credit any overpayment to Deposit Account No. 50-1922. Should the Examiner have any questions, please do not hesitate to call Applicant's attorney at 832-446-2421.

Respectfully submitted,

By 

Marilyn M. Huston

Reg. No. 37,851

Wong, Cabello, Lutsch, Rutherford & Brucculeri, L.L.P.

20333 SH 249, Suite 600

Houston, TX 77070

(832) 446-2421

### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted by facsimile to the USPTO Central Facsimile Number (703) 872-9306, according to 37 CFR § 1.6 (d) on May 19, 2004.

  
Marilyn M. Huston